Multiple Sclerosis Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Biogen, Immune Response BioPharma, Celgene, Novartis, Sanofi, Actelion, Bayer

Multiple Sclerosis Pipeline 2026 highlights a crowded development landscape for therapies across key companies and multiple trial stages. Based on DelveInsight’s assessment, the global multiple sclerosis pipeline involves 75+ companies pursuing 80+ treatment therapies, spanning pre-clinical through marketed phases. The report covers mechanisms of action, routes of administration, clinical studies, and potential NDA approvals, alongside collaborations and funding activities. Among named companies are Biogen, Sanofi, Novartis, Celgene, Bayer and others, with emerging candidates including BIIB091, NeuroVax, IMCY-0141, ATA188, SAR441344, Temelimab, IMU-838 and Tolebrutinib. In June 2026, the European Commission approved Cenrifki (tolebrutinib) for adults with secondary progressive multiple sclerosis who remained relapse-free for two years, citing the Phase III HERCULES trial and supporting GEMINI 1 and GEMINI 2 data. The article also notes FDA clearance of an IND for PTD802 by Pheno Therapeutics Limited.